Steven Cohen Erasca, Inc. Transaction History
Point72 Asset Management, L.P.
- $40.1 Billion
- Q1 2025
A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Erasca, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 40,522 shares of ERAS stock, worth $70,508. This represents 0.0% of its overall portfolio holdings.
Number of Shares
40,522
Previous 40,522
-0.0%
Holding current value
$70,508
Previous $55,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding ERAS
# of Institutions
164Shares Held
222MCall Options Held
20.6KPut Options Held
5.7K-
Frazier Life Sciences Management, L.P. Menlo Park, CA22.6MShares$39.3 Million1.95% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD17.3MShares$30.1 Million0.02% of portfolio
-
Vr Adviser, LLC New York, NY16.2MShares$28.2 Million5.36% of portfolio
-
Logos Global Management LP San Francisco, CA13MShares$22.6 Million3.47% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.7MShares$22.1 Million0.0% of portfolio
About Erasca, Inc.
- Ticker ERAS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 122,147,000
- Market Cap $213M
- Description
- Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...